drugset / Trial / NCT04603989
A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics
Phase 1
Completed
36 enrolled
Guangzhou Henovcom Bioscience Co. Ltd.
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to evaluate the safety , tolerability and pharmacokinetics after multiple ascending of HNC042 given to healthy Chinese volunteers, compared to placebo.
Timeline
- Start
- 2020-08-01
- Primary completion
- 2020-11-13
- Completion
- 2020-11-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HNC042 | Unknown | 300 mg | Intravenous |
| Subject | HNC042 | Unknown | 1200 mg | Intravenous |